Celcuity posts narrower-than-expected loss as R&D costs decreased
Celcuity posts narrower-than-expected loss as R&D costs decreased
Overview
US biotechnology firm's Q2 adjusted loss per share beat analyst expectations
Q2 adjusted net loss also beat analyst expectations
Operating expenses rose due to commercial launch preparations for REVTORPYK
Outlook
Company expects to begin shipping REVTORPYK late in the third quarter 2026
Celcuity plans to submit sNDA for gedatolisib in the third quarter 2026
Company expects to provide clinical updates on prostate cancer and subcutaneous formulation in Q4 2026
Result Drivers
COMMERCIAL LAUNCH PREPARATIONS - Co said higher SG&A expenses were mainly due to hiring and costs related to the anticipated launch of REVTORPYK
R&D COST CHANGES - Co said R&D expenses fell due to lower clinical trial and license milestone costs, partly offset by higher employee and manufacturing costs
CLINICAL AND REGULATORY MILESTONES - Co highlighted FDA approval of REVTORPYK and positive Phase 3 trial results as key recent achievements
Company press release: ID:nGNX71LfK5
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Adjusted Loss Per Share | Beat | $1.07 | $1.16 (11 Analysts) |
Q2 Loss Per Share |
| $1.44 |
|
Q2 Adjusted Net Loss | Beat | $58.70 mln | $60.51 mln (9 Analysts) |
Q2 Net Loss |
| $78.90 mln |
|
Q2 Operating Expenses |
| $66.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc. is $165.00, about 79.2% above its August 12 closing price of $92.08
Reuters Recommended Reads
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
Aug 12 - Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake
Aug 11 - Legend Biotech Q2 revenue beats estimates on commercial expansion
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)